Related Experiment Videos
Intravitreal bevacizumab for the treatment of refractory diabetic macular edema
Sachin Mehta1, Kevin J Blinder, Gaurav K Shah
1Department of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Background And Objective:
To report the effect of intravitreal bevacizumab on visual acuity and central retinal thickness (CRT) in refractory diabetic macular edema.
Patients And Methods:
Records of 60 eyes of 54 consecutive patients who underwent intravitreal bevacizumab therapy for refractory diabetic macular edema were reviewed. All eyes received intravitreal bevacizumab 1.25 mg/0.05 mL, and 36 eyes underwent pretreatment and post-treatment optical coherence tomography. Mean follow-up was 7.4 months.
Results:
Pretreatment mean visual acuity plus or minus standard deviation was 0.71 +/- 0.28 logarithm of the minimum angle of resolution (LogMAR) Snellen letters. At final follow-up, mean visual acuity had improved to 0.66 +/- 0.30 LogMAR (P = .0543). Mean baseline CRT was 440 +/- 106 microm, and follow-up mean CRT was 386 +/- 129 microm (P = .008). Vitrectomized eyes had worse visual acuity and CRT outcomes (P = .002 and P = .028, respectively) compared with nonvitrectomized eyes.
Conclusion:
Intravitreal bevacizumab may provide a functional and anatomic benefit in eyes with persistent diabetic macular edema despite previous treatments.
Related Concept Videos
Diabetic Retinopathy
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment